Proteolysis resistant active vegf
AssigneeBayer Innovation GmbH
InventorsSabine Eming, Thomas Krieg, Stephan Sollberg, Gereon Lauer
Life of this patent
Estimating the term…
Abstract
The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
Claims20
A vascular endothelial growth factor (VEGF) variant, comprising an amino acid sequence, wherein said sequence is the amino acid sequence of the native vascular endothelial growth factor in which at least one amino acid at positions 109 to 112 of the native vascular endothelial growth factor is replaced by another amino acid or is deleted.
(canceled)
Dependencies are inferred from the claim text.